Core Insights - Surrozen, Inc. is focused on developing targeted therapeutics that modulate the Wnt pathway for tissue repair and regeneration, particularly in severe eye diseases [1][2] Business Highlights - The company is concentrating on its ophthalmology pipeline, utilizing its expertise in Wnt biology and antibody technologies to create new treatments for severe eye diseases [2] Leadership Changes - Andrew Maleki has been appointed as Chief Financial Officer, bringing over a decade of biotech experience and a track record of raising over $500 million in capital [4][5] - Charles Williams will continue as Chief Operating Officer, focusing on strategic initiatives and corporate development [6][7] Financial Performance - As of September 30, 2025, cash and cash equivalents were $81.3 million, down from $90.4 million as of June 30, 2025 [8] - Collaboration and license revenue was zero for the quarter, compared to $10 million for the same period in 2024, due to the recognition of a milestone in September 2024 [8] - The net loss for the quarter was $71.6 million, or $8.36 per share, compared to a net loss of $1.4 million, or $0.44 per share, for the same period in 2024 [13][23] Ophthalmology Pipeline - Surrozen is advancing its lead candidates, SZN-8141 and SZN-8143, for retinal diseases and plans to submit an Investigational New Drug (IND) application for SZN-8141 in 2026 [9] - SZN-8141 combines Frizzled 4 (Fzd4) agonism and Vascular Endothelial Growth Factor (VEGF) antagonism, showing potential benefits over existing treatments for Diabetic Macular Edema (DME) and wet Age-Related Macular Degeneration [14] - SZN-8143 combines Fzd4 agonism, VEGF antagonism, and interleukin-6 (IL-6) antagonism, which may offer advantages for treating DME, wet AMD, and uveitic macular edema [15] Strategic Partnerships - Surrozen has a partnership with Boehringer Ingelheim for SZN-413, a bi-specific antibody targeting Fzd4-mediated Wnt signaling, which has shown promise in preclinical models for retinal diseases [16][18]